

1 ***Leishmania* infection triggers hepcidin-mediated proteasomal degradation of Nramp1**
2 **resulting in increased phagolysosomal iron availability**

3

4 Sourav Banerjee and Rupak Datta[#]

5

6

7 Department of Biological Sciences, Indian Institute of Science Education and Research (IISER)

8 Kolkata, Mohanpur, West Bengal, INDIA

9

10

11 [#]To whom correspondence to be addressed.

12 Rupak Datta

13 E-mail: rupakdatta@iiserkol.ac.in

14 Tel: +91 033 6136 0000; Extn: 1214

15 ORCID identifier: 0000-0003-1820-9251

16

17

18 Running title: *Leishmania* infection-induced degradation of Nramp1

19 Key words: Nramp1, Slc11a1, *Leishmania*, iron, macrophage, hepcidin, proteasome

20 Abstract word count: 250

21 Text word count: 5459

22 **Abstract**

23 Natural resistance associated macrophage protein 1 (Nramp1) was discovered as a genetic
24 determinant of resistance against multiple intracellular pathogens, including *Leishmania*. It
25 encodes a transmembrane protein of the phago-endosomal vesicles, where it functions as an iron
26 transporter. But how Nramp1 expression is regulated in an infected macrophage is unknown. Its
27 role in controlling iron availability to the intracellular pathogens and in determining the final
28 outcome of an infection also remains to be fully deciphered. Here we report that Nramp1 protein
29 abundance undergoes temporal changes in *Leishmania major* infected macrophages. At 12 hours
30 post infection, there was drastic lowering of Nramp1 level accompanied by increased
31 phagolysosomal iron availability and enhanced parasite growth. *Leishmania* infection-induced
32 downregulation of Nramp1 was found to be caused by ubiquitin-proteasome degradation
33 pathway. In fact, blocking of Nramp1 degradation with proteasome inhibitor resulted in
34 depletion of phagolysosomal iron pool with significant reduction in the number of intracellular
35 parasites. Further, we uncovered that this degradation process is mediated by the iron regulatory
36 peptide hormone hepcidin that binds to Nramp1. Interestingly, Nramp1 protein level was
37 restored to normalcy after 30 hours of infection with a concomitant drop in the phagolysosomal
38 iron level, which is suggestive of a host counter defense strategy to deprive the pathogen of this
39 essential micronutrient. Taken together, our study implicates Nramp1 as a central player in the
40 host-pathogen battle for iron. It also unravels Nramp1 as a novel partner for hepcidin. The
41 hitherto unidentified ‘hepcidin-Nramp1 axis’ may have a broader role in regulating macrophage
42 iron homeostasis.

43

44 **Importance**

45 *Leishmania* parasites are the causative agents of a group of neglected tropical diseases called
46 leishmaniasis. They reside within the phagolysosomes of mammalian macrophages. Since iron is
47 an essential micronutrient for survival and virulence, intracellular *Leishmania* must acquire it
48 from the tightly regulated macrophage iron pool. How this challenging task is accomplished
49 remains a fundamental question in *Leishmania* biology. We report here that *Leishmania major*
50 infection caused ubiquitin-proteasome-mediated degradation of natural resistance associated
51 macrophage protein 1 (Nramp1). Nramp1 being an iron exporter at the phago-endosomal
52 membrane, its degradation resulted in increased phagolysosomal iron availability thereby
53 stimulating parasite growth. We also uncovered that Nramp1 degradation is controlled by the
54 iron regulatory peptide hormone hepcidin. Interestingly, at a later stage of infection, Nramp1
55 protein level was restored to normalcy with simultaneous depletion of phagolysosomal iron.
56 Collectively, our study implicates Nramp1 as a central player in the host-pathogen struggle for
57 acquiring iron.

58

59 **Introduction**

60 *Leishmania* belongs to the trypanosomatid group of protozoan parasites and they are the
61 causative agents for a spectrum of human diseases collectively known as leishmaniasis.
62 Depending on the *Leishmania* species, severity of the disease varies from self-resolving skin
63 ulcers to life threatening infection of the visceral organs. With about 12 million currently
64 affected people from nearly 100 endemic countries and more than 1 million new cases every
65 year, leishmaniasis imposes a significant challenge to the global healthcare system (1, 2).
66 Unavailability of a vaccine, limited chemotherapeutic options and increasing signs of drug
67 resistance further aggravated the problem (3). Better understanding of *Leishmania* physiology
68 and the mechanisms which enable the parasite to survive in host environment is therefore
69 required to conceive novel strategies for effectively combating this disease.

70 *Leishmania* promastigotes are transmitted to humans by bite of a sand fly. Thereafter, they are
71 rapidly phagocytosed by the macrophages either directly or via engulfment of parasite containing
72 apoptotic neutrophils (4). Upon internalization, the parasites are delivered to the phagolysosome
73 where they differentiate into the amastigote form and continue to proliferate till the cell bursts
74 (5). While traversing through the phagosome maturation pathway, *Leishmania* has to overcome
75 multitude of host-induced stress factors, including oxidative and nitrosative stresses, before
76 encountering the low pH and hydrolytic enzyme-rich environment of the phagolysosome. Apart
77 from facing these challenges, *Leishmania* amastigotes also have to scavenge all the essential
78 nutrients from resource-limited phagolysosomal environment (6, 7). To subvert such adversaries,
79 *Leishmania* parasites encode various nutrient acquisition genes and are also armored with
80 defenses against free radicals, intracellular acidosis and lysosomal hydrolases (5, 8–11).
81 Moreover, intracellular *Leishmania* also have the distinctive ability to manipulate host gene

82 expression to adapt itself to the harsh environment (12–15). However, there has been very little
83 effort to understand the molecular basis of these reprogramming events in *Leishmania* infected
84 macrophages and to exploit them for anti-leishmanial drug discovery.

85 Genetic makeup of the host is also a critical factor in determining susceptibility to leishmaniasis
86 and severity of the symptoms (16, 17). Linkage analysis and genome wide association studies led
87 to identification of many disease modifier genes or genetic loci in mouse as well as in human
88 (18, 19). Most prominent among them is the natural resistance associated macrophage protein 1
89 (Nramp1), which was originally identified as the *Bcg/Ity/Lsh* locus in the mouse chromosome 1.
90 Mice expressing Nramp1 were shown to be resistant to diverse group of pathogens, such as
91 *Mycobacteria*, *Salmonella* and *Leishmania* (20). Furthermore, data from human population-
92 based studies demonstrated association between Nramp1 polymorphism and susceptibility to
93 wide varieties of infectious diseases, including visceral and cutaneous leishmaniasis (21–23).
94 Nramp1 belongs to the solute carrier protein family 11 (hence also known as SLC11A1) and is
95 predicted to be an integral membrane protein with 12 transmembrane helices (24). It is
96 exclusively expressed in the phagocytes where it was found to be localized in the lysosomes/late
97 endosomes as well as in the membrane of maturing phagosomes/phagolysosomes (25, 26).
98 Interestingly, a naturally occurring point mutation (G169D) in the fourth transmembrane domain
99 of Nramp1 prevented proper maturation of the protein and the mice harboring this mutation were
100 vulnerable to different types of infections (20, 27). Functional characterization of Nramp1
101 uncovered its role as an iron transporter at the phagosomal membrane, however, the direction of
102 iron trafficking remained a matter of controversy (24, 28). Increased cytoplasmic influx of iron
103 observed in Nramp1 expressing cells supported the role of Nramp1 in mobilizing iron from
104 phagosomal compartment into the cytoplasm. This led to the hypothesis that functional Nramp1

105 restricts pathogen growth by depriving them of iron, which is an essential micronutrient (29, 30).
106 However, there are contradictory reports suggesting Nramp1 imports iron into the phagosomes
107 where it catalyzes generation of hydroxyl radical and thereby inflicting oxidative damage to the
108 pathogens (31, 32). Thus, despite its proven role in conferring resistance against a wide variety
109 of pathogenic infections, there is still some ambiguity regarding the mode of action of Nramp1.
110 Also, whether Nramp1 status is modulated during the course of an infection and how its function
111 influences the outcome of host pathogen interaction remains completely unknown. In this work
112 we addressed these unresolved issues in a macrophage infection model for *Leishmania major*.
113 We report here that *Leishmania* infection results in ubiquitin-proteasome-mediated degradation
114 of macrophage Nramp1 at 12 hours post infection followed by almost complete recovery of
115 Nramp1 level after 30 hours. Nramp1 downregulation at 12 hours post infection led to increased
116 availability of iron within the phagolysosomes and enhanced intracellular parasite growth.
117 Interestingly, our work also revealed that hepcidin, an iron regulatory peptide hormone, binds
118 with Nramp1 and facilitates its degradation (33). Thus, besides identifying a hitherto unknown
119 strategy by which intracellular *Leishmania* modulates host's iron withholding machinery for its
120 own survival benefit, this study unraveled the role of hepcidin-Nramp1 signaling axis in
121 regulating the macrophage iron recycling process.

122 **Results**

123 **Nramp1 is recruited to the phagolysosomes in *L. major* infected macrophages**

124 Although Nramp1 is known to mediate resistance against various intracellular pathogens,
125 whether its own status is altered during the course of infection is unknown. To address this, we
126 first sought to compare subcellular distribution of Nramp1 in uninfected versus *L. major* infected
127 macrophages by immunofluorescence staining. It was revealed that in uninfected J774A.1 cells

128 (a BALB/c mouse derived macrophage cell line), Nramp1 was distributed in punctate
129 intracellular structures, which colocalized strongly with Rab11 positive endocytic vesicles (PCC:
130 0.93 ± 0.028) and to a lesser extent with the lysosomal marker, Lamp1 (PCC: 0.43 ± 0.06).
131 Whereas, in *L. major* infected macrophages, Nramp1 was found to reside mostly in the
132 Rab11/Lamp1 double-positive vesicles (PCC for Rab11: 0.89 ± 0.05 , PCC for Lamp1: 0.67 ± 0.09)
133 at 12 hours post infection (Fig. 1A to D). These results suggest that Nramp1 is preferentially
134 recruited to the phagolysosomal compartment upon *L. major* infection. It is also worth noting
135 that there was a marked reduction in the Nramp1 protein level in *L. major* infected macrophages
136 as compared to their uninfected counterparts (Fig. 1A and B). This intriguing finding prompted
137 us to undertake a systematic analysis of the relative abundance of Nramp1 during the course of
138 *L. major* infection.

139 **Temporal modulation of Nramp1 protein level in *L. major* infected macrophages**

140 Following the lead from the previous experiment, we infected J774A.1 macrophages with *L.*
141 *major* promastigotes and then Nramp1 protein level was visualized by immunofluorescence
142 staining at different time points after infection (2 – 30 hours). Although Nramp1 expression
143 remained almost unaltered at early time points after infection (2 or 6 hours), there was a
144 significant reduction in its level (by > 50%) at 12 hours post infection. Interestingly, the level of
145 Nramp1 was almost restored to normalcy at a later time point i.e. 30 hours post infection (Fig.
146 2A to D). The status of Nramp1 in J774A.1 macrophages during the course of infection was
147 independently verified by western blot analysis, the results of which are in complete agreement
148 with our immunofluorescence data (Fig. S1). Before proceeding further, we also wanted to
149 validate our cell line-based data in a primary macrophage cell. For this we isolated thioglycolate
150 elicited peritoneal macrophages from BALB/c mice and infected those cells with *L. major*

151 promastigotes. As seen earlier in J774A.1 cell line, Nramp1 protein level in *L. major* infected
152 peritoneal macrophages underwent drastic reduction at 12 hours post infection but reverted
153 almost to the normal level after 30 hours (Fig. S2). Collectively, these data provided
154 unambiguous evidence that cellular abundance of the Nramp1 protein indeed changes during the
155 course of infection, which is possibly an outcome of the complex dynamics of host pathogen
156 interaction.

157 **Downregulation of Nramp1 in *L. major* infected macrophages resulted in increased**
158 **phagolysosomal iron content and higher intracellular parasite burden**

159 Since Nramp1 is as a phagosomal/phagolysosomal iron transporter, the next obvious question
160 was whether this significant drop in the Nramp1 level at 12 hours post infection has any
161 functional implication in regulating iron availability within the phagosomal/phagolysosomal
162 compartments (25). For this, we isolated Nramp1/Rab11 double positive phagosomal/
163 phagolysosomal fraction from both uninfected and *L. major* infected J774A.1 macrophages by
164 sucrose density gradient centrifugation and measured iron content in them by ferrozine-based
165 colorimetric assay (Fig. 3A to C). We observed that iron content in the
166 phagosomes/phagolysosomes isolated from *L. major* infected macrophages at 12 hours post
167 infection was nearly double than in those isolated from the uninfected cells (Fig. 3D). This
168 correlation between decreased Nramp1 protein level and increased phagosomal/phagolysosomal
169 iron concentration is consistent with the reported role of Nramp1 as a phagosomal iron exporter
170 (29, 30). This was further validated when phagosomal/phagolysosomal iron content was
171 measured at 30 hours post infection, the time point by which Nramp1 protein level was almost
172 restored to normalcy. By this time there was a significant drop in the
173 phagosomal/phagolysosomal iron concentration in the infected cells and it became almost

174 comparable to that in the uninfected cells (Fig. 3D). Interestingly, at 12 hours post infection,
175 increased phagosomal/phagolysosomal iron content coincided with maximum intracellular
176 parasite burden measured over the time course of infection (Fig. 3E). This data reconfirmed the
177 role of iron as a vital nutrient for *Leishmania* parasites residing in the phagolysosomal niche
178 (34).

179 ***L. major* infection caused Nramp1 degradation via ubiquitin-proteasomal pathway**

180 To investigate the mechanism by which *L. major* infection causes downregulation of Nramp1,
181 we first compared Nramp1 transcript levels in uninfected and *L. major* infected J774A.1
182 macrophages at 12 hours post infection. From our RT-qPCR data it is evident that transcription
183 of Nramp1 remained unaltered, suggesting that its downregulation in *Leishmania* infected cells
184 occurs via a post-transcriptional mechanism (Fig. 4A). We next examined the role of
185 proteasomal activity in degradation of Nramp1. For this J774A.1 macrophages were treated with
186 the proteasome inhibitor, MG132, immediately after infection with *L. major* and the Nramp1
187 protein level was visualized by immunofluorescence staining at 12 hours post infection (35).
188 MG132 treatment completely prevented *Leishmania* infection-induced downregulation of
189 Nramp1, implying that its degradation is mediated by the proteasomal machinery (Fig. 4B and
190 C). This result was also independently validated by western blot analysis (Fig. S3). Since
191 proteasomal substrates are usually ubiquitinated prior to degradation, we decided to check the
192 ubiquitination status of Nramp1 in uninfected and *L. major* infected J774A.1 macrophages at 12
193 hours post infection (36). Whole cell lysate immunoprecipitation with anti-Nramp1 followed by
194 western blot with ubiquitin antibody confirmed that ubiquitination of Nramp1 was significantly
195 increased upon *Leishmania* infection thus making it an ideal target for proteasomal degradation
196 (Fig. 4D).

197 **Nramp1 stabilization upon proteasomal inhibition resulted in decreased phagolysosomal**
198 **iron content and lowering of intracellular parasite burden**

199 Since the data presented in Fig. 3 indicated that Nramp1 exports iron from the
200 phagosomes/phagolysosomes, we were prompted to check whether iron concentration in these
201 compartments is decreased when Nramp1 in *L. major* infected macrophages is stabilized by
202 inhibition of proteasomal activity. At 12 hours post infection, MG132-treated macrophages
203 indeed had significantly lower phagosomal/phagolysosomal iron content than the infected cells
204 that were not treated with the proteasomal inhibitor. In fact, phagosomal/phagolysosomal iron
205 content in the MG132-treated, *L. major* infected macrophages was almost same as in the
206 uninfected macrophages (Fig. 5A). Importantly, MG132 treatment also led to significant
207 lowering of the intracellular parasite burden in the macrophages, which is likely to be a result of
208 iron limiting phagolysosomal environment (Fig. 5B).

209 ***L. major* infection-induced hepcidin surge in the macrophage is responsible for Nramp1**
210 **degradation, enrichment of phagolysosomal iron pool and enhanced parasite growth**

211 Infection of macrophages with *L. amazonensis* was earlier shown to induce transcription of the
212 iron regulatory peptide hormone hepcidin, which in turn caused degradation of the cell surface
213 iron exporter ferroportin. This led to increased intracellular parasite growth, presumably due to
214 enhanced macrophage iron content (37). However, ferroportin downregulation would increase
215 the cytosolic iron pool, which cannot be directly accessed by the *Leishmania* parasites residing
216 within the phagolysosomal compartment (37–39). So, it remained unclear
217 how *Leishmania* infection-induced upregulation of hepcidin could stimulate intracellular parasite
218 growth. Since Nramp1 closely resembles ferroportin in terms of its iron exporting property and
219 membrane topology with 12 transmembrane helices, we decided to check if its expression is also

220 regulated by hepcidin (24, 40). For this, we first validated the status of hepcidin expression in *L.*
221 *major* infected J774A.1 macrophages. Consistent with the earlier results obtained with *L.*
222 *amazonensis* infection, we observed sharp increase in hepcidin mRNA and protein levels in the
223 *L. major* infected macrophages as compared to their uninfected counterparts (Fig. S4A and B)
224 (37). It is worth noting that in the infected macrophages, hepcidin was found to be mostly
225 distributed in vesicular compartments suggesting that it may have important intracellular role(s)
226 in addition to its well-known paracrine action (Fig. S4B) (41). To check if Nramp1 expression is
227 indeed regulated by intracellular hepcidin, we decided to treat the cells with heparin, an
228 established transcriptional blocker for hepcidin that restricted hepcidin up-regulation in *L. major*
229 infected macrophages (Fig. 6A) (42). Interestingly, treatment of the macrophages with heparin
230 provided complete protection against *L. major* infection-induced downregulation of Nramp1
231 protein level without affecting cell viability as revealed by our immunofluorescence data as well
232 as western blot analysis (Fig. 6B and C; and Fig. S5A to C). Increased Nramp1 level in heparin
233 treated macrophages was accompanied by significantly reduced phagosomal iron content, which
234 resulted in drastic lowering of intracellular parasite burden (Fig. 6D and E). Co-
235 immunoprecipitation assay further demonstrated physical interaction of hepcidin with Nramp1
236 indicating that hepcidin binding may induce ubiquitination and proteasome-mediated
237 degradation of Nramp1 similar to what has been earlier reported for ferroportin (Fig. 6F) (43,
238 44). Taken together our data strongly suggest that Nramp1 degradation in *L. major* infected
239 macrophages occurs via hepcidin-dependent autocrine pathway, which is critical for maintaining
240 an iron rich phagolysosomal environment required for parasite growth.

241 **Discussion**

242 Influence of host genetic factors on the outcome of *Leishmania* infection is widely reported (16–
243 19). Among all the infection modifier genes, Nramp1 is particularly significant since it confers
244 resistance not only to *Leishmania* infection but also to two other unrelated pathogens viz.
245 *Mycobacteria* and *Salmonella* (20). Although the function of Nramp1 as a phago-endosomal iron
246 transporter is well-established, there are conflicting reports with respect to the direction of iron
247 transport (24, 28–32). So far there has been no attempt to investigate how Nramp1 expression is
248 regulated in an infected cell or how it controls iron availability to intracellular pathogens. Hence,
249 the mechanism by which Nramp1 acts against the invading pathogens remains poorly
250 understood. In this scenario, our work is the first comprehensive study of Nramp1 expression in
251 the context of an infection. Employing macrophage infection model of *L. major*, we made an
252 interesting observation that Nramp1 protein level undergoes time-dependent changes during the
253 course of *Leishmania* infection. First, at 12 hours post infection, there was a drastic reduction in
254 the level of Nramp1 which was followed by near-complete recovery of expression at 30 hours.
255 Downregulation of Nramp1 was accompanied by increased phagolysosomal iron content and
256 enhanced intracellular parasite growth. We also report that *Leishmania* infection-induced
257 downregulation of Nramp1 is caused by ubiquitin-proteasomal degradation, which in turn is
258 mediated by the iron modulatory peptide hormone hepcidin (33). Taken together, our study
259 highlights Nramp1 as a central player in the battle for iron between the host and the pathogen
260 where each of them tries to tinker Nramp1 protein level to modulate phagolysosomal iron
261 content. Moreover, our study uncovers Nramp1 as a novel target of hepcidin, in addition to its
262 well-established target ferroportin. A proposed model describing the role of this hitherto
263 unidentified hepcidin-Nramp1 axis in regulating phagolysosomal iron level in response to
264 *Leishmania* infection is described in Fig. 7.

265 It was previously reported that in uninfected macrophages Nramp1 resides in the endocytic
266 compartments, which are involved in phagolysosome biogenesis (25, 26, 45). Upon *L. major*
267 infection, Nramp1 was found in the membrane of the pathogen-containing phagolysosomes
268 thereby raising the question whether it can influence the parasite microenvironment by virtue of
269 its iron transport activity (26). Corroborating evidence was provided by our immunofluorescence
270 study that revealed recruitment of Nramp1 to the Rab11/Lamp1 double-positive phagolysosomal
271 compartments in *L. major* infected macrophages. Unexpectedly, we also noticed a significant
272 reduction in the Nramp1 protein expression at 12 hours post infection. This prompted us to
273 investigate if reduced Nramp1 level in *Leishmania* infected macrophages resulted in any change
274 in the phagolysosomal iron content. Addressing this issue was crucial for understanding the
275 mechanism by which Nramp1 counteracts intracellular pathogens. Indeed, at 12 hours post
276 infection, there was almost two folds increase in phagolysosomal iron level in *L. major* infected
277 macrophages as compared to their uninfected counterparts. Our data thus established an inverse
278 relationship between Nramp1 protein level and phagosomal/phagolysosomal iron content, which
279 is supportive of the notion that Nramp1 transports iron from intracellular vesicles to the cytosol
280 (29, 30). This notion was further strengthened by the observation that at 30 hours post infection
281 Nramp1 expression reverted to the normal level with concomitant decrease in the
282 phagosomal/phagolysosomal iron content.

283 Growth and survival of *Leishmania*, like other intracellular pathogens, is critically dependent on
284 the availability of iron and their ability to scavenge it from the surroundings (34, 46, 47). Since
285 iron pool in mammals is tightly regulated, the battle between the host and the pathogen for this
286 essential micronutrient has often been found to be a key determinant of the infection outcome
287 (48). Recently, Ben-Othman *et. al.* reported that *L. amazonensis* infection triggered

288 downregulation of ferroportin, the macrophage cell surface iron exporter, as a strategy to
289 enhance intracellular iron level and promote parasite growth (37). However, it remained unclear
290 how this augmented cytosolic iron pool is accessed by *Leishmania*, which resides within the
291 phagolysosomal compartment. In this regard, our work unraveled an alternative Nramp1-
292 targeted iron-scavenging mechanism by which *Leishmania* infection increases phagolysosomal
293 iron level that can be directly taken up by the parasite employing its own iron transporter (49–
294 51). It was therefore not surprising that intracellular parasite count peaked at 12 hours post
295 infection, the time at which phagolysosomal iron level was also at its maximum because of
296 stunted Nramp1 expression. But what caused reversal of Nramp1 expression to the normal level
297 at 30 hours post infection is somewhat mysterious. From our data it appears to be a host defense
298 response designed to create an iron-limiting microenvironment for the invading pathogens so as
299 to restrict their propagation.

300 After having established infection-induced downregulation of Nramp1 as a novel iron-
301 sequestering strategy of *Leishmania*, attempts were made to obtain mechanistic insights of this
302 process. Several important macrophage genes, especially those linked with immune response
303 against pathogens, were shown to be transcriptionally repressed upon *Leishmania* infection (13–
304 15). But the possibility of transcriptional inhibition was ruled out in this case as there was no
305 difference in the Nramp1 transcript level between uninfected and *Leishmania* infected
306 macrophages. Rather, Nramp1 downregulation at 12 hours post infection was found to be
307 completely blocked by treatment with the proteasome inhibitor, MG132. This result along with
308 the observation that Nramp1 ubiquitination was significantly enhanced in *Leishmania* infected
309 macrophages supported the conclusion that infection-induced downregulation of Nramp1 is
310 mediated by ubiquitin-proteasomal degradation pathway (36). There are multiple reports

311 confirming direct involvement of *Leishmania* surface protease GP63 in degradation of host
312 proteins as a tool to manipulate macrophage signaling and function (52–55). However, engaging
313 the host proteasomal machinery to selectively target a host protein is somewhat unique and
314 seems to be a clever tactic employed by the parasite to alter the phagolysosomal
315 microenvironment. To the best of our knowledge there is only one such prior study where *L.*
316 *donovani* infection was shown to subvert JAK2/STAT1 α signaling pathway in macrophage
317 through proteasomal degradation of STAT1 α (56). It is worth noting that MG132-mediated
318 stabilization of Nramp1 was accompanied with significantly reduced phagolysosomal iron
319 content resulting in more than fifty percent lowering of intracellular parasite burden. Based on
320 the available data it is thus tempting to speculate that inhibition of macrophage proteasome might
321 be an effective way to target intracellular *Leishmania*. Apart from depriving the pathogen of iron,
322 proteasome inhibition may also restore JAK2/STAT1 α signaling pathway of the macrophage and
323 activate cytokine-mediated antiparasitic immune response (57). Selective targeting of
324 *Leishmania* proteasome has recently shown the promise to treat visceral leishmaniasis in
325 preclinical studies (58, 59). But the possibility of mammalian proteasome-directed anti-
326 leishmanial therapy is yet to be explored. Since an FDA approved mammalian proteasome
327 inhibitor (bortezomib) is already available, such host-directed, multitarget therapeutic approach
328 is worth pursuing, which may provide a new direction towards treatment of this neglected
329 disease (60).

330 What triggered ubiquitination and proteasomal degradation of Nramp1 is yet to be fully
331 understood. However, an important lead in this direction was provided by our serendipitous
332 finding that infection-induced degradation of Nramp1 is dependent on the iron regulatory peptide
333 hormone hepcidin. Strikingly, heparin-mediated inhibition of hepcidin transcription not only

334 blocked Nramp1 degradation but this treatment also resulted in depletion of phagolysosomal iron
335 pool and drastic lowering of intracellular parasite burden. In a recent report, *L. amazonensis*
336 infection was shown to upregulate transcription of hepcidin in macrophage, which in turn caused
337 degradation of the cell surface iron exporter ferroportin (37). Prior to this work, an extensive
338 body of research has demonstrated that hepcidin binding triggers rapid ubiquitination of
339 ferroportin thereby inducing its internalization and degradation (43, 44). In view of this, our co-
340 immunoprecipitation data showing physical interaction between Nramp1 and hepcidin is quite
341 intriguing. Whether this interaction is indeed responsible for Nramp1 ubiquitination followed by
342 its degradation cannot be ascertained unequivocally at this point and such causal relationship
343 needs to be validated with follow-up studies. However, this seems to be a likely possibility since:
344 a) Nramp1 was protected from infection-induced degradation when hepcidin expression was
345 downregulated. Therefore, hepcidin, either alone or in association with other molecular partners,
346 must be playing a critical role in degrading Nramp1; b) Nramp1 is topologically identical to
347 ferroportin, with 12 transmembrane domains, hence both may follow similar hepcidin-mediated
348 degradation mechanism (40). Although hepcidin is primarily produced by the hepatocytes and
349 acts on the macrophage ferroportin in a paracrine fashion, there are few reports confirming its
350 endogenous expression in the macrophages in response to different infections and inflammatory
351 stimuli (61–63). It was also reported that macrophage-produced hepcidin may act on the cell
352 surface localized ferroportin in an autocrine fashion to sequester iron in those cells (64). But the
353 mechanism by which hepcidin is retained within the macrophage and act on an intracellular
354 target like Nramp1 needs to be investigated in details to better understand the functional
355 implications of hepcidin-Nramp1 axis. Our work is an important first step towards this direction.
356 Since Nramp1 is reported to facilitate efficient macrophage iron recycling following

357 erythrophagocytosis, this hitherto unidentified hepcidin-Nramp1 axis may have a broader
358 regulatory role in maintaining iron homeostasis in the phagocytic cells (65, 66).

359 **Materials and Methods**

360 Unless mentioned specifically, all reagents were purchased from Sigma-Aldrich. Primers for
361 PCR were obtained from Integrated DNA Technologies.

362 **Antibodies**

363 A rabbit polyclonal antibody was raised against mouse Nramp1 using a synthetic peptide
364 (³²¹LQNYAKIFPRDN³³⁴) from C- terminal region of the protein as antigen (IMGENEX India
365 custom antibody generation facility). The antibody was validated by western blot analysis using
366 J774A.1 macrophage whole cell lysate. Anti-Lamp1 antibody (Abcam) and anti- Rab11 antibody
367 (Santa- Cruz Biotechnology) were kind gifts of Dr. Arnab Gupta (IISER Kolkata). Rabbit
368 polyclonal antibody raised against human hepcidin polypeptide was a generous gift of Dr.
369 William S. Sly (Saint Louis University School of Medicine).

370 **Parasite and mammalian cell culture**

371 The *L. major* strain 5ASKH was kindly provided by Dr. Subrata Adak (IICB, Kolkata). *L. major*
372 promastigotes were cultured in M199 medium (Gibco) pH 7.2, supplemented with 15% heat-
373 inactivated fetal bovine serum (FBS, Gibco), 23.5 mM HEPES, 0.2mM adenine, 150 µg/ml folic
374 acid, 10 µg/ml hemin, 120 U/ml penicillin, 120 µg/ml streptomycin, and 60 µg/ml gentamicin at
375 26°C. J774A.1 cells (murine macrophage cell line obtained from National Center for Cell
376 Sciences, Pune) were grown in Dulbecco's modified Eagle's medium (DMEM, Gibco) pH 7.4
377 supplemented with 2 mM L-glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin, and 10%
378 heat-inactivated FBS at 37°C in a humidified atmosphere containing 5% CO₂. Cell number was
379 quantified using a hemocytometer (10).

380 **Isolation of peritoneal macrophages from BALB/c mice**

381 BALB/c mice were obtained from the National Institute of Nutrition (NIN), Hyderabad, and
382 housed in our institutional animal facility. Experiments with these mice were conducted
383 according to the CPCSEA guidelines and Institutional Animal Ethics Committee approved
384 protocol. Thioglycolate elicited peritoneal macrophages were isolated from 6- 8 weeks old mice
385 as described earlier (67). Briefly, 4 days after intraperitoneal injection of 3% Brewer's
386 thioglycolate medium (Himedia), mice were euthanized and peritoneal macrophages were
387 collected using 20 G needle. Thereafter the isolated macrophages were cultured in DMEM pH
388 7.4 supplemented with 2 mM L-glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin, and
389 10% heat-inactivated FBS at 37°C in a humidified atmosphere containing 5% CO₂. Non-
390 adherent cells were discarded between 18- 24 h. Cellular viability was determined using trypan
391 blue dye exclusion test.

392 ***L. major* infection of macrophages and determination of intracellular parasite burden**

393 Infection of J774A.1 or primary peritoneal macrophages with *L. major* promastigotes was
394 performed as described by us previously (10). Briefly, the macrophages were activated with 100
395 ng/ml lipopolysaccharide (LPS) for 6 hours. *L. major* promastigotes were then added to the
396 macrophages at a ratio of 30:1 (parasite: macrophage) and the infection was allowed to continue
397 for 2, 6 or 12 hours, as indicated. For 30 hours infection, J774A.1 macrophages were first
398 incubated with *L. major* promastigotes for 12 hours following which the parasites were removed
399 and the infected macrophage cells were incubated for another 18 hours. In each case, uninfected
400 cells similarly treated with LPS served as control. After infection, cells were washed, fixed with
401 acetone-methanol (1:1) and mounted with anti-fade mounting medium containing DAPI
402 (VectaShield from Vector Laboratories). Intracellular parasite burden (number of

403 amastigotes/100 macrophages) was quantified by counting the total number of DAPI-stained
404 nuclei of macrophages and *L. major* amastigotes in a field (at least 100 macrophages were
405 counted from triplicate experiments). During pharmacological inhibition studies cells were either
406 treated with 1 μ M MG132 (kindly provided by Dr. Partho Sarothi Ray, IISER Kolkata) or 4
407 μ g/ml heparin.

408 **Immunofluorescence studies and image analysis**

409 Macrophages grown on glass coverslips were fixed using acetone: methanol (1: 1) for 10 minutes
410 at room temperature. After two washes with PBS, cells were permeabilized using 0.1 % triton- X
411 100. Cells were washed again with PBS and blocked with 0.2% gelatin for 5min at room
412 temperature. Cells were then incubated with desired primary antibodies (anti-Nramp1 1: 50; anti-
413 Rab11 1: 200; and anti-Lamp1 1:20) for 1.5 hours at room temperature and thereafter washed
414 with PBS. Cells were then incubated with either of the following secondary antibodies
415 (Molecular Probes), goat anti-rabbit Alexa fluor 488 (1: 800), goat anti-mouse Alexa fluor 568
416 (1: 600) or donkey anti-goat Cy3 (1: 800) and washed with PBS. Finally, the cells were mounted
417 on anti-fade mounting medium containing DAPI and imaged in Carl Zeiss Apotome.2
418 microscope using 63X oil immersion objectives or in Olympus IX-81 epifluorescence
419 microscope using either 40X or 60X objectives. In colocalization experiments Pearson's
420 correlation coefficient (PCC) was calculated as described previously (68). Relative fluorescence
421 intensity was measured using microscope's own software ZEN Blue (fluorescence intensities of
422 more than 100 macrophages were measured from triplicate experiments).

423 **Phagosome isolation and Iron quantification**

424 Phagosomes from both uninfected and *L. major* infected J774A.1 macrophage cells were isolated
425 using the sucrose density gradient centrifugation as described previously (69). Isolated

426 phagosomes were subjected to western blot to verify the presence of both Nramp1 and Rab11 in
427 the desired fraction. The primary antibody dilutions were: anti- Nramp1 antibody (1: 500) and
428 anti- Rab11 antibody (1: 1000). Following the overnight incubation with primary antibodies at
429 4°C blots were probed with HRP- conjugated goat anti- rabbit or rabbit anti- goat secondary
430 antibodies respectively at 1: 4000 dilutions. Phagosomal iron (Fe^{2+}) was quantified using
431 ferrozine assay as reported earlier (70). Briefly, 100 μL of phagosomal fraction was incubated
432 with 100 μL 10mM HCl, 4.5% KMnO_4 for 2 hours at 60°C. After this samples were cooled down
433 and further incubated with iron detection reagent (that contains 6.5mM ferrozine, 6.5mM
434 neocuproine, 2.5M ammonium acetate and 1M ascorbic acid) for 30 mins. Thereafter, the
435 absorbance was measured at 550nm using microplate reader. A standard curve was prepared
436 using varying concentration of FeCl_3 (0- 300 μM) and the iron concentration in experimental
437 samples was derived from the standard curve.

438 **Co-Immunoprecipitation assay**

439 To assess ubiquitination status of Nramp1, whole cell lysates were subjected to
440 immunoprecipitation (IP) with anti-Nramp1 followed by immunoblotting with anti-ubiquitin
441 antibody. Briefly, J774A.1 macrophage cells were either uninfected or infected with *L. major* for
442 12 hours following which cellular proteins were extracted in lysis buffer containing 150 mM
443 NaCl, 10mM EDTA, 10mM Tris (pH 7.4), 1% Triton X-100 and protease inhibitor cocktail.
444 Lysates containing equal amount of protein were incubated with 60 μl of Protein A PLUS
445 Agarose Beads (BioBharati Life Science Pvt. Ltd., India) for 15min at 4°C and centrifuged at
446 3000rpm for 2min (71). The supernatant was incubated with 5 μl of anti- Nramp1 overnight
447 at 4°C in mild shaking. Thereafter 60 μl of Protein A PLUS Agarose Bead was added to it and
448 incubated for 4 hours at 4°C followed by centrifugation. The immunoprecipitates were washed

449 twice with 1.0ml lysis buffer and dissolved in 100 μ l sample buffer. The samples were then
450 subjected to SDF-PAGE followed by western blot using either anti-ubiquitin or Nramp1
451 antibody. To determine the binding of hepcidin and Nramp1 we performed immunoprecipitation
452 using Thermo Scientific Pierce Co-IP kit (kindly provided by Dr. Piyali Mukherjee of Presidency
453 University, Kolkata) following the manufacturer's protocol. At first anti- Nramp1 was coupled to
454 AminoLink Plus resin, which was then used for the immunoprecipitation assay following similar
455 method as described above. Covalent coupling of the antibody to the resin provides an advantage
456 over the traditional Co-IP methods that use Protein A or G resulting in co-elution of the antibody
457 heavy and light chains. Presence of either hepcidin or Nramp1 in the immunoprecipitates was
458 determined by immunodot blot method using the corresponding antibodies.

459 **Western blot and immunodot blot**

460 Uninfected and infected J774A.1 macrophage cells were washed twice with ice cold PBS and
461 scrapped to collect it in a centrifuge tube. Cell suspension was centrifuged at 3000 rpm for 5
462 min. The cell pellet was resuspended in lysis buffer containing PBS, protease inhibitor cocktail
463 and was sonicated to prepare whole cell lysate. The whole cell lysates were subjected to SDS-
464 PAGE and Nramp1 protein level was determined using western blot. Anti- Nramp1 antibody was
465 used at a dilution of 1: 1000 and anti- γ -Actin antibody (Bio-Bharati) was used at a dilution of 1:
466 4000. HRP-conjugated goat anti-rabbit secondary antibody was used at a dilution of 1: 4000.
467 The blots were developed using SuperSignal West Pico Chemiluminescent Substrate (Pierce).
468 Quantification of the band intensity was performed using ImageJ software. Hepcidin levels in the
469 whole cell lysate or immunoprecipitate were determined by immunodot blot assay as described
470 previously (72). For this, the samples were spotted directly on the PVDF membrane and probed

471 with anti-hepcidin, anti-Nramp1 or anti- γ -Actin primary antibodies at a dilution of 1: 2000 for
472 each. HRP- conjugated goat anti- rabbit secondary antibody was used at a dilution of 1: 7000.

473 **RNA isolation and q RT-PCR**

474 Total RNA was isolated from both uninfected and infected macrophages using TRIzol reagent
475 (Invitrogen). These were further treated with DNaseI (Invitrogen) to remove any DNA
476 contaminations. The cDNA was synthesized using Verso cDNA synthesis kit (Thermo) from 1 μ g
477 of total RNA. Transcript level of different genes was quantified using the following primers:
478 mouse Nramp1- Forward 5'- TTACTCACTCGGACCAGCAC-3', mouse Nramp1 Reverse 5'-
479 GGGGGCTCTTGTCACTAATCAT-3'; mouse Hecpidin Forward 5'-
480 TGTCTCCTGCTTCTCCTCCT- 3', mouse hepcidin Reverse 5'- CTCTGTAGTCTGTCTCAT-
481 3'; β - Actin Forward 5'- GGCTGTATTCCCCTCCATCG-3', beta- Actin Reverse 5'-
482 CCAGTTGGTAACAATGCCATG T-3'. Real time PCR was performed using 7500 real time
483 PCR system of applied Biosystems with SYBR green fluorophore (BioRad). Transcript levels of
484 either Nramp1 or Hecpidin were normalized with respect to β - Actin expression in each of the
485 sample.

486 **Statistical analysis**

487 All statistical analyses were executed by Student's t test or one-way ANOVA calculator. The
488 results were represented as mean \pm SD from minimum 3 independent experiments. P values of
489 ≤ 0.05 were considered statistically significant and levels of statistical significance were indicated
490 as follows: * $p \leq 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$.

491 **Acknowledgements**

492 The authors sincerely thank Mr. Ritabrata Ghosh, Mr. Dipesh Dutta and Mr. Sujoy Bose for their
493 expert technical assistance. Drs. William S. Sly, Abdul Waheed and Piyali Mukherjee are
494 acknowledged for helpful suggestions and for providing critical reagents used in this work.

495 This work was supported by IISER Kolkata intramural fund. S. Banerjee was supported by DST
496 INSPIRE PhD fellowship.

497 The authors declare no competing financial interests.

498 Author contributions: S. Banerjee designed and performed the experiments, analyzed the data
499 and assisted in manuscript writing. R. Datta conceptualized and supervised the work, analyzed
500 the data, acquired funds and wrote the manuscript.

501 **References**

- 502 1. Burza S, Croft SL, Boelaert M. 2018. Leishmaniasis. *Lancet* (London, England) 392:951–
503 970.
- 504 2. Okwor I, Uzonna J. 2016. Social and Economic Burden of Human Leishmaniasis. *Am J*
505 *Trop Med Hyg* 94:489–493.
- 506 3. Croft SL, Sundar S, Fairlamb AH. 2006. Drug resistance in leishmaniasis. *Clin Microbiol*
507 *Rev* 19:111–26.
- 508 4. Peters NC, Egen JG, Secundino N, Debrabant A, Kimblin N, Kamhawi S, Lawyer P, Fay
509 MP, Germain RN, Sacks D. 2008. In vivo imaging reveals an essential role for neutrophils
510 in leishmaniasis transmitted by sand flies. *Science* 321:970–4.
- 511 5. Chang KP, Dwyer DM. 1978. *Leishmania donovani*. Hamster macrophage interactions in
512 vitro: cell entry, intracellular survival, and multiplication of amastigotes. *J Exp Med*
513 147:515–30.
- 514 6. Thi EP, Lambertz U, Reiner NE. 2012. Sleeping with the Enemy: How Intracellular

- 515 Pathogens Cope with a Macrophage Lifestyle. PLoS Pathog 8:e1002551.
- 516 7. Haas A. 2007. The Phagosome: Compartment with a License to Kill. Traffic 8:311–330.
- 517 8. Burchmore RJ, Barrett MP. 2001. Life in vacuoles--nutrient acquisition by *Leishmania*
- 518 amastigotes. Int J Parasitol 31:1311–20.
- 519 9. Van Assche T, Deschacht M, da Luz RAI, Maes L, Cos P. 2011. *Leishmania*–macrophage
- 520 interactions: Insights into the redox biology. Free Radic Biol Med 51:337–351.
- 521 10. Pal DS, Abbasi M, Mondal DK, Varghese BA, Paul R, Singh S, Datta R. 2017. Interplay
- 522 between a cytosolic and a cell surface carbonic anhydrase in pH homeostasis and acid
- 523 tolerance of *Leishmania*. J Cell Sci 130:754–766.
- 524 11. Späth GF, Garraway LA, Turco SJ, Beverley SM. 2003. The role(s) of lipophosphoglycan
- 525 (LPG) in the establishment of *Leishmania* major infections in mammalian hosts. Proc Natl
- 526 Acad Sci U S A 100:9536–41.
- 527 12. Gregory DJ, Sladek R, Olivier M, Matlashewski G. 2008. Comparison of the Effects of
- 528 *Leishmania* major or *Leishmania donovani* Infection on Macrophage Gene Expression.
- 529 Infect Immun 76:1186–1192.
- 530 13. Beverley SM. 1996. Hijacking the cell: parasites in the driver’s seat. Cell 87:787–9.
- 531 14. Carrera L, Gazzinelli RT, Badolato R, Hieny S, Muller W, Kuhn R, Sacks DL. 1996.
- 532 *Leishmania* promastigotes selectively inhibit interleukin 12 induction in bone marrow-
- 533 derived macrophages from susceptible and resistant mice. J Exp Med 183:515–526.
- 534 15. Buates S, Matlashewski G. 2001. General Suppression of Macrophage Gene Expression
- 535 During *Leishmania donovani* Infection. J Immunol 166:3416–3422.
- 536 16. Sakthianandeswaren A, Foote SJ, Handman E. 2009. The role of host genetics in
- 537 leishmaniasis. Trends Parasitol 25:383–391.

- 538 17. Jeronimo SMB, Duggal P, Ettinger NA, Nascimento ET, Monteiro GR, Cabral AP, Pontes
539 NN, Lacerda HG, Queiroz PV, Gomes CEM, Pearson RD, Blackwell JM, Beaty TH,
540 Wilson ME. 2007. Genetic Predisposition to Self-Curing Infection with the Protozoan
541 *Leishmania chagasi*: A Genomewide Scan. *J Infect Dis* 196:1261–1269.
- 542 18. Blackwell JM, Fakiola M, Ibrahim ME, Jamieson SE, Jeronimo SB, Miller EN, Mishra A,
543 Mohamed HS, Peacock CS, Raju M, Sundar S, Wilson ME. 2009. Genetics and visceral
544 leishmaniasis: of mice and man. *Parasite Immunol* 31:254–66.
- 545 19. Mohamed HS, Ibrahim ME, Miller EN, Peacock CS, Khalil EAG, Cordell HJ, Howson
546 JMM, El Hassan AM, Bereir REH, Blackwell JM. 2003. Genetic susceptibility to visceral
547 leishmaniasis in The Sudan: linkage and association with IL4 and IFNGR1. *Genes Immun*
548 4:351–355.
- 549 20. Vidal SM, Malo D, Vogan K, Skamene E, Gros P. 1993. Natural resistance to infection
550 with intracellular parasites: isolation of a candidate for Bcg. *Cell* 73:469–85.
- 551 21. Bucheton B, Abel L, Kheir MM, Mirgani A, El-Safi SH, Chevillard C, Dessein A. 2003.
552 Genetic control of visceral leishmaniasis in a Sudanese population: candidate gene testing
553 indicates a linkage to the NRAMP1 region. *Genes Immun* 4:104–109.
- 554 22. Mohamed HS, Ibrahim ME, Miller EN, White JK, Cordell HJ, Howson JMM, Peacock
555 CS, Khalil EAG, El Hassan AM, Blackwell JM. 2004. SLC11A1 (formerly NRAMP1)
556 and susceptibility to visceral leishmaniasis in The Sudan. *Eur J Hum Genet* 12:66–74.
- 557 23. Fattahi-Dolatabadi M, Mousavi T, Mohammadi-Barzelighi H, Irian S, Bakhshi B,
558 Nilforoushzadeh M-A, Shirani-Bidabadi L, Hariri M-M, Ansari N, Akbari N. 2016.
559 NRAMP1 gene polymorphisms and cutaneous leishmaniasis: An evaluation on host
560 susceptibility and treatment outcome. *J Vector Borne Dis* 53:257–63.

- 561 24. Gruenheid S, Skamene E, Gros P. 1999. Nramp1: A novel macrophage protein with a key
562 function in resistance to intracellular pathogens. *Adv Cell Mol Biol Membr Organelles*
563 5:345–362.
- 564 25. Gruenheid S, Pinner E, Desjardins M, Gros P. 1997. Natural resistance to infection with
565 intracellular pathogens: the Nramp1 protein is recruited to the membrane of the
566 phagosome. *J Exp Med* 185:717–30.
- 567 26. Searle S, Bright NA, Roach TI, Atkinson PG, Barton CH, Meloen RH, Blackwell JM.
568 1998. Localisation of Nramp1 in macrophages: modulation with activation and infection. *J*
569 *Cell Sci* 111 (Pt 19):2855–66.
- 570 27. Vidal SM, Pinner E, Lepage P, Gauthier S, Gros P. 1996. Natural resistance to
571 intracellular infections: Nramp1 encodes a membrane phosphoglycoprotein absent in
572 macrophages from susceptible (Nramp1 D169) mouse strains. *J Immunol* 157:3559–68.
- 573 28. Atkinson PG, Barton CH. 1998. Ectopic expression of Nramp1 in COS-1 cells modulates
574 iron accumulation. *FEBS Lett* 425:239–42.
- 575 29. Atkinson PG, Barton CH. 1999. High level expression of Nramp1G169 in RAW264.7 cell
576 transfectants: analysis of intracellular iron transport. *Immunology* 96:656–62.
- 577 30. Barton CH, Biggs TE, Baker ST, Bowen H, Atkinson PGP. 1999. *Nramp1* : a link
578 between intracellular iron transport and innate resistance to intracellular pathogens. *J*
579 *Leukoc Biol* 66:757–762.
- 580 31. Kuhn DE, Baker BD, Lafuse WP, Zwilling BS. 1999. Differential iron transport into
581 phagosomes isolated from the RAW264.7 macrophage cell lines transfected with Nramp1
582 ^{Gly169} or Nramp1 ^{Asp169}. *J Leukoc Biol* 66:113–119.
- 583 32. Zwilling BS, Kuhn DE, Wikoff L, Brown D, Lafuse W. 1999. Role of iron in Nramp1-

- 584 mediated inhibition of mycobacterial growth. *Infect Immun* 67:1386–92.
- 585 33. Drakesmith H, Prentice AM. 2012. Hepcidin and the Iron-Infection Axis. *Science* (80-)
586 338:768–772.
- 587 34. Flannery AR, Renberg RL, Andrews NW. 2013. Pathways of iron acquisition and
588 utilization in *Leishmania*. *Curr Opin Microbiol* 16:716–721.
- 589 35. Lee DH, Goldberg AL. 1998. Proteasome inhibitors: valuable new tools for cell biologists.
590 *Trends Cell Biol* 8:397–403.
- 591 36. Collins GA, Goldberg AL. 2017. The Logic of the 26S Proteasome. *Cell* 169:792–806.
- 592 37. Ben-Othman R, Flannery AR, Miguel DC, Ward DM, Kaplan J, Andrews NW. 2014.
593 *Leishmania*-Mediated Inhibition of Iron Export Promotes Parasite Replication in
594 Macrophages. *PLoS Pathog* 10:e1003901.
- 595 38. Chang K, Dwyer D. 1976. Multiplication of a human parasite (*Leishmania donovani*) in
596 phagolysosomes of hamster macrophages in vitro. *Science* (80-) 193:678–680.
- 597 39. McConville MJ, de Souza D, Saunders E, Likic VA, Naderer T. 2007. Living in a
598 phagolysosome; metabolism of *Leishmania* amastigotes. *Trends Parasitol* 23:368–375.
- 599 40. Wallace DF, Harris JM, Subramaniam VN. 2010. Functional analysis and theoretical
600 modeling of ferroportin reveals clustering of mutations according to phenotype. *Am J*
601 *Physiol Physiol* 298:C75–C84.
- 602 41. Nemeth E, Ganz T. 2006. Regulation of Iron Metabolism by Heparin. *Annu Rev Nutr*
603 26:323–342.
- 604 42. Poli M, Girelli D, Campostrini N, Maccarinelli F, Finazzi D, Luscieti S, Nai A, Arosio P.
605 2011. Heparin: a potent inhibitor of hepcidin expression in vitro and in vivo. *Blood*
606 117:997–1004.

- 607 43. Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, Ganz T, Kaplan
608 J. 2004. Heparin Regulates Cellular Iron Efflux by Binding to Ferroportin and Inducing
609 Its Internalization. *Science* (80-) 306:2090–2093.
- 610 44. Qiao B, Sugianto P, Fung E, del-Castillo-Rueda A, Moran-Jimenez M-J, Ganz T, Nemeth
611 E. 2012. Heparin-Induced Endocytosis of Ferroportin Is Dependent on Ferroportin
612 Ubiquitination. *Cell Metab* 15:918–924.
- 613 45. Desjardins M, Huber LA, Parton RG, Griffiths G. 1994. Biogenesis of phagolysosomes
614 proceeds through a sequential series of interactions with the endocytic apparatus. *J Cell*
615 *Biol* 124:677–688.
- 616 46. Mitra B, Cortez M, Haydock A, Ramasamy G, Myler PJ, Andrews NW. 2013. Iron
617 uptake controls the generation of *Leishmania* infective forms through regulation of ROS
618 levels. *J Exp Med* 210:401–16.
- 619 47. Das NK, Biswas S, Solanki S, Mukhopadhyay CK. 2009. *Leishmania donovani* depletes
620 labile iron pool to exploit iron uptake capacity of macrophage for its intracellular growth.
621 *Cell Microbiol* 11:83–94.
- 622 48. Sutak R, Lesuisse E, Tachezy J, Richardson DR. 2008. Crusade for iron: iron uptake in
623 unicellular eukaryotes and its significance for virulence. *Trends Microbiol* 16:261–8.
- 624 49. Jacques I, Andrews NW, Huynh C. 2010. Functional characterization of LIT1, the
625 *Leishmania amazonensis* ferrous iron transporter. *Mol Biochem Parasitol* 170:28–36.
- 626 50. Flannery AR, Huynh C, Mitra B, Mortara RA, Andrews NW. 2011. LFR1 Ferric Iron
627 Reductase of *Leishmania amazonensis* Is Essential for the Generation of Infective Parasite
628 Forms. *J Biol Chem* 286:23266–23279.
- 629 51. Huynh C, Sacks DL, Andrews NW. 2006. A *Leishmania amazonensis* ZIP family iron

- 630 transporter is essential for parasite replication within macrophage phagolysosomes. *J Exp*
631 *Med* 203:2363–2375.
- 632 52. Gomez MA, Contreras I, Halle M, Tremblay ML, McMaster RW, Olivier M. 2009.
633 *Leishmania* GP63 Alters Host Signaling Through Cleavage-Activated Protein Tyrosine
634 Phosphatases. *Sci Signal* 2:ra58–ra58.
- 635 53. Contreras I, Gómez MA, Nguyen O, Shio MT, McMaster RW, Olivier M. 2010.
636 *Leishmania*-Induced Inactivation of the Macrophage Transcription Factor AP-1 Is
637 Mediated by the Parasite Metalloprotease GP63. *PLoS Pathog* 6:e1001148.
- 638 54. Hallé M, Gomez MA, Stuible M, Shimizu H, McMaster WR, Olivier M, Tremblay ML.
639 2009. The *Leishmania* Surface Protease GP63 Cleaves Multiple Intracellular Proteins and
640 Actively Participates in p38 Mitogen-activated Protein Kinase Inactivation. *J Biol Chem*
641 284:6893–6908.
- 642 55. Isnard A, Shio MT, Olivier M. 2012. Impact of *Leishmania* metalloprotease GP63 on
643 macrophage signaling. *Front Cell Infect Microbiol* 2:72.
- 644 56. Forget G, Gregory DJ, Olivier M. 2005. Proteasome-mediated degradation of
645 STAT1alpha following infection of macrophages with *Leishmania donovani*. *J Biol Chem*
646 280:30542–9.
- 647 57. Murray PJ. 2007. The JAK-STAT signaling pathway: input and output integration. *J*
648 *Immunol* 178:2623–9.
- 649 58. Wyllie S, Brand S, Thomas M, De Rycker M, Chung C-W, Pena I, Bingham RP, Bueren-
650 Calabuig JA, Cantizani J, Cebrian D, Craggs PD, Ferguson L, Goswami P, Hobrath J,
651 Howe J, Jeacock L, Ko E-J, Korczynska J, MacLean L, Manthri S, Martinez MS, Mata-
652 Cantero L, Moniz S, Nühs A, Osuna-Cabello M, Pinto E, Riley J, Robinson S, Rowland P,

- 653 Simeons FRC, Shishikura Y, Spinks D, Stojanovski L, Thomas J, Thompson S, Viayna
654 Gaza E, Wall RJ, Zuccotto F, Horn D, Ferguson MAJ, Fairlamb AH, Fiandor JM, Martin
655 J, Gray DW, Miles TJ, Gilbert IH, Read KD, Marco M, Wyatt PG. 2019. Preclinical
656 candidate for the treatment of visceral leishmaniasis that acts through proteasome
657 inhibition. *Proc Natl Acad Sci U S A* 116:9318–9323.
- 658 59. Khare S, Nagle AS, Biggart A, Lai YH, Liang F, Davis LC, Barnes SW, Mathison CJN,
659 Myburgh E, Gao M-Y, Gillespie JR, Liu X, Tan JL, Stinson M, Rivera IC, Ballard J, Yeh
660 V, Groessl T, Federe G, Koh HXY, Venable JD, Bursulaya B, Shapiro M, Mishra PK,
661 Spraggon G, Brock A, Mottram JC, Buckner FS, Rao SPS, Wen BG, Walker JR, Tuntland
662 T, Molteni V, Glynn RJ, Supek F. 2016. Proteasome inhibition for treatment of
663 leishmaniasis, Chagas disease and sleeping sickness. *Nature* 537:229–233.
- 664 60. Kane RC, Bross PF, Farrell AT, Pazdur R. 2003. Velcade: U.S. FDA approval for the
665 treatment of multiple myeloma progressing on prior therapy. *Oncologist* 8:508–13.
- 666 61. Peyssonnaud C, Zinkernagel AS, Datta V, Lauth X, Johnson RS, Nizet V. 2006. TLR4-
667 dependent hepcidin expression by myeloid cells in response to bacterial pathogens. *Blood*
668 107:3727.
- 669 62. Nguyen N-B, Callaghan KD, Ghio AJ, Haile DJ, Yang F. 2006. Hepcidin expression and
670 iron transport in alveolar macrophages. *Am J Physiol Cell Mol Physiol* 291:L417–L425.
- 671 63. Sow FB, Florence WC, Satoskar AR, Schlesinger LS, Zwilling BS, Lafuse WP. 2007.
672 Expression and localization of hepcidin in macrophages: a role in host defense against
673 tuberculosis. *J Leukoc Biol* 82:934–945.
- 674 64. Theurl I, Theurl M, Seifert M, Mair S, Nairz M, Rumpold H, Zoller H, Bellmann-Weiler
675 R, Niederegger H, Talasz H, Weiss G. 2008. Autocrine formation of hepcidin induces iron

- 676 retention in human monocytes. *Blood* 111:2392–2399.
- 677 65. Soe-Lin S, Apte SS, Andriopoulos B, Andrews MC, Schranzhofer M, Kahawita T, Garcia-
678 Santos D, Ponka P. 2009. Nramp1 promotes efficient macrophage recycling of iron
679 following erythrophagocytosis in vivo. *Proc Natl Acad Sci* 106:5960–5965.
- 680 66. Soe-Lin S, Sheftel AD, Wasyluk B, Ponka P. 2008. Nramp1 equips macrophages for
681 efficient iron recycling. *Exp Hematol* 36:929–937.
- 682 67. Zhang X, Goncalves R, Mosser DM. 2008. The Isolation and Characterization of Murine
683 Macrophages, p. 14.1.1-14.1.14. *In Current Protocols in Immunology*. John Wiley &
684 Sons, Inc., Hoboken, NJ, USA.
- 685 68. MCDONALD JH, DUNN KW. 2013. Statistical tests for measures of colocalization in
686 biological microscopy. *J Microsc* 252:295–302.
- 687 69. Mukherjee K, Parashuraman S, Krishnamurthy G, Majumdar J, Yadav A, Kumar R, Basu
688 SK, Mukhopadhyay A. 2002. Diverting intracellular trafficking of Salmonella to the
689 lysosome through activation of the late endocytic Rab7 by intracellular delivery of
690 muramyl dipeptide. *J Cell Sci* 115:3693–701.
- 691 70. Riemer J, Hoepken HH, Czerwinska H, Robinson SR, Dringen R. 2004. Colorimetric
692 ferrozine-based assay for the quantitation of iron in cultured cells. *Anal Biochem*
693 331:370–375.
- 694 71. LOWRY OH, ROSEBROUGH NJ, FARR AL, RANDALL RJ. 1951. Protein
695 measurement with the Folin phenol reagent. *J Biol Chem* 193:265–75.
- 696 72. Schwarz P, Strnad P, von Figura G, Janetzko A, Krayenbühl P, Adler G, Kulaksiz H.
697 2011. A novel monoclonal antibody immunoassay for the detection of human serum
698 hepcidin. *J Gastroenterol* 46:648–656.

699 **Abbreviations**

700 Nramp1: Natural resistance associated macrophage protein 1; Slc11a1: Solute carrier family 11
701 member 1; *L. major*: *Leishmania major*

702 **Figure Legends**

703 **FIG 1** Nramp1 is recruited to the phagolysosomes in *L. major* infected macrophages.

704 (A and B) J774A.1 macrophages were infected with *L. major* (Lm) and co-immunostained with
705 anti-Nramp1 (green) and anti- Rab11 (cyan red) (A) or anti-Nramp1 (green) and anti-Lamp1
706 (red) (B) at 12hrs post infection. The merged images represent colocalization of the proteins
707 (yellow). Nuclei were stained with DAPI (blue). Uninfected macrophage cells were used as
708 control. White arrows indicate the presence of intracellular parasites in infected cells (smaller
709 nuclei). Cells were visualized with Zeiss Apotome microscope using 63X oil immersion
710 objective. Scale bar: 20µm. (C and D) Bar diagrams represents Pearson's colocalization
711 coefficient (PCC) of Nramp1 with Rab11 (C) or with Lamp1 (D) measured using ImageJ
712 software. Grey bar represents uninfected macrophages whereas black bar represents Lm infected
713 macrophages. At least 20 cells from three independent experiments were scored in each of the
714 cases. Error bars represent standard error mean (SEM). **, $p \leq 0.01$; ****, $p \leq 0.0001$.

715 **FIG 2** Alteration of Nramp1 protein level during the course of *L. major* infection.

716 (A-D) Nramp1 protein level was visualized by immunostaining with anti-Nramp1 (green) in
717 uninfected or *L. major* (Lm) infected J774A.1 macrophages at different time points post
718 infection (2- 30hrs). Nuclei were stained with DAPI (blue). Arrows in the Lm infected panel
719 indicates the presence of intracellular parasites (smaller nuclei). Cells were visualized under 63X
720 oil immersion objective of Zeiss Apotome microscope. Scale bar: 20µm. Lower panel represents
721 the quantitative estimation of Nramp1 expression as indicated by the relative fluorescence

722 intensity of Nramp1 at indicated time points in uninfected (grey bar) and Lm infected (black bar)
723 macrophage cells. Several fields were imaged using Olympus IX-81 epifluorescence microscope
724 and at least 100 macrophage cells were analyzed for the fluorescence intensity measurement
725 using ZEN software of the microscope. Uninfected cells were used as reference sample during
726 quantification. Error bars represent SEM calculated from three independent experiments. ****,
727 $p \leq 0.0001$; n.s., non-significant.

728 **FIG 3** Downregulation of Nramp1 in *L. major* infected macrophages resulted in increased
729 phagosomal/phagolysosomal iron content and higher intracellular parasite burden.

730 (A) Schematic diagram showing subcellular fractionation to isolate phagosomes/phagolysosomes
731 from macrophage cells using sucrose density gradient centrifugation followed by ferrozine-based
732 iron estimation assay. (B and C) Western blot of the subcellular fractions prepared from
733 uninfected (B) and *L. major* (Lm) infected (C) macrophage cells at 12hrs post infection (p.i.)
734 using anti- Nramp1 and anti- Rab11 antibody to verify the presence of both Nramp1 and Rab11 at
735 their predicted molecular weight of ~100 kDa and 24 kDa respectively. (D) Bar diagram
736 representing phagosomal/phagolysosomal iron content as measured by ferrozine assay in
737 uninfected (grey bar) and Lm infected (black bar) macrophage cells at 12hrs and 30hrs p.i. Error
738 bars represents SEM values calculated from at least three independent experiments. (E)
739 Intracellular parasite burden in Lm infected macrophage cells measured over 2- 48hrs p.i.
740 Intracellular parasite burden (amastigotes/ 100 macrophages) was quantified from at least 100
741 macrophage cells. Error bars represent SEM values calculated from at least three independent
742 experiments. **, $p \leq 0.01$; ****, $p \leq 0.0001$.

743 **FIG 4** *L. major* infection causes Nramp1 degradation via ubiquitin-proteasomal pathway.

744 (A) Representative bar diagram showing Nramp1 transcript level in uninfected (grey bar) and *L.*
745 *major* (Lm) infected (black bar) macrophage cells at 12hrs post infection determined by RT-
746 qPCR using β - Actin as endogenous control gene and uninfected cell as reference sample. Error
747 bars represent SEM values calculated from 3 independent experiments. **, $p \leq 0.01$. (B) Nramp1
748 protein level was examined by immunostaining using anti- Nramp1 (green) in uninfected, Lm
749 infected and 1 μ M MG132 treated Lm infected J774A.1 macrophage cells at 12hrs post infection.
750 DAPI (blue) was used to stain *Leishmania* and macrophage cell nuclei. Arrows indicate the
751 presence of intracellular parasites in Lm infected macrophages. Cells were visualized with Zeiss
752 Apotome microscope using 63X oil immersion objective. Scale bar: 20 μ m. (C) Bar diagram
753 depicts relative fluorescence intensity of Nramp1 in uninfected (grey bar), Lm infected (black
754 bar) and 1 μ M MG132 treated Lm infected macrophage cells (white bar). Fluorescence intensity
755 was measured from at least 100 macrophage cells imaged under Olympus IX-81 epifluorescence
756 microscope using ZEN software. During quantification uninfected cells were considered as
757 reference sample. Error bars represent SEM values calculated from three independent
758 experiments. **, $p \leq 0.01$. (D) Western blot to verify the ubiquitination status of Nramp1 protein.
759 Both uninfected and Lm infected J774A.1 macrophage cells at 12hrs post infection (p.i.) were
760 lysed and cell lysates were analyzed for ubiquitination of Nramp1 by immuno-precipitation (IP)
761 using anti- Nramp1 antibody followed by immunoblotting (IB) with anti- ubiquitin antibody (top
762 panel). Uniform level of protein input was verified by IP as well as IB with anti- Nramp1 (lower
763 panel).

764 **FIG 5** Nramp1 stabilization upon proteasomal inhibition resulted in decreased phagolysosomal
765 iron content and lowering of intracellular parasite burden.

766 (A) Bar diagram representing phagosomal iron content as measured by ferrozine assay in
767 uninfected (grey bar), *L. major* (Lm) infected (black bar) and 1 μ M MG132 treated Lm infected
768 (white bar) J774A.1 macrophage cells at 12hrs post infection as described earlier. Error bars
769 represent SEM values calculated from at least three independent experiments. (B) Bar diagram
770 showing amastigotes/ 100 macrophages count either in Lm infected (black) or in 1 μ M MG132
771 treated Lm infected (white) J774A.1 macrophage cells. Error bars represent SEM values
772 calculated from at least 100 macrophage cells of three independent experiments. **, $p \leq 0.01$;
773 ****, $p \leq 0.0001$.

774 **FIG 6** *L. major* infection-induced hepcidin upregulation in macrophage is responsible for
775 Nramp1 degradation.

776 (A) Bar diagram showing RT-qPCR data of hepcidin transcript level in uninfected (grey bar), *L.*
777 *major* (Lm) infected (black bar) and 4 μ g/ml heparin treated Lm infected J774A.1 macrophage
778 cells (stripped bar) at 12hrs post infection. All the measurements were performed using
779 uninfected cell as reference sample and β - actin as an endogenous control gene. Error bars
780 represent SEM values calculated from three independent experiments. *, $p \leq 0.05$. (B) Nramp1
781 protein level was observed by immunostaining using anti- Nramp1 (green) in uninfected, Lm
782 infected and 4 μ g/ml heparin treated Lm infected J774A.1 macrophage cells at 12hrs post
783 infection. *Leishmania* and macrophage nuclei were stained with DAPI (blue). Arrows indicate
784 the presence of intracellular parasites in Lm infected macrophages. Cells were visualized with
785 Zeiss Apotome microscope using 63X oil immersion objective. Scale bar: 20 μ m. (C) Bar graph
786 showing relative fluorescence intensity of Nramp1 measured using ZEN software from at least
787 100 macrophage cells of uninfected (grey bar), Lm infected (black bar) and heparin treated Lm
788 infected macrophage cells (stripped bar) imaged under Olympus IX-81 epifluorescence

789 microscope. Error bars represent SEM values calculated from three independent experiments. *,
790 $p \leq 0.05$; **, $p \leq 0.01$. (D) Bar diagram showing phagosomal/phagolysosomal iron level as
791 measured by ferrozine assay in uninfected (grey bar), *L. major* (Lm) infected (black bar) and
792 4 μ g/ml heparin treated Lm infected (stripped bar) J774A.1 macrophage cells at 12hrs post
793 infection. (E) Intracellular parasite burden in Lm infected (black bar) and 4 μ g/ml heparin treated
794 Lm infected (stripped bar) J774A.1 macrophage cells at 12 hrs p.i. Amastigotes/ 100
795 macrophages was measured from at least 100 macrophage cells of three independent experiments
796 as detailed previously. Error bars represent SEM values calculated from the experiments. **,
797 $p \leq 0.01$; ****, $p \leq 0.0001$. (F) Both uninfected and Lm infected J774A.1 macrophage cells at
798 12hrs post infection were lysed and cell lysates were immuno-precipitated (IP) using anti-
799 Nramp1 antibody. Either whole cell lysates of those cells (input) in left panel or
800 immunoprecipitated (IP) samples in the right panel were subjected to immunodot blot (IB) with
801 anti-hepcidin and anti-Nramp1 to verify the presence of these proteins. Immunodot blot with
802 anti- γ Actin served as loading control.

803 **FIG 7** Proposed model for the *L. major* infection-induced degradation of macrophage Nramp1
804 and its impact on phagolysosomal iron content.

805 Macrophage cells export iron from the phagosomal/phagolysosomal lumen to the cytosol via the
806 action of Nramp1. While the cells become infected with *Leishmania*, it stimulates synthesis of
807 iron regulatory peptide hormone hepcidin. In these infected cells, hepcidin binds with Nramp1,
808 eventually causing its degradation via ubiquitine-proteasomal degradation pathway. The loss of
809 Nramp1 results into the accumulation of iron within *Leishmania* containing phagolysosomal
810 compartment that favors the replication of the parasite.

811 **FIG S1** *L. major* infection-induced downregulation of Nramp1 at 12hrs post infection.

812 J774A.1 macrophage cells were either uninfected or infected with *L. major* (Lm) for 2-30 hours.
813 After indicated time points post infection (p.i.), cells were lysed and Nramp1 protein level was
814 determined in whole cell lysates by western blot. Blots were probed with anti- Nramp1 and anti-
815 γ -Actin (loading control) antibody where both Nramp1 and γ -Actin bands appeared at their
816 predicted molecular weight of ~100 and 42 kDa respectively. Lower panel shows the relative
817 intensity of Nramp1 protein in uninfected (grey bar) and Lm infected (black bar) macrophages
818 measured using ImageJ software. During quantification uninfected cell was used as reference
819 sample and γ -Actin as endogenous control protein. Error bars represent SEM values calculated
820 from at least three independent experiments and normalized to respective control. ****,
821 $p \leq 0.0001$.

822 **FIG S2** Nramp1 protein level is reduced in *L. major* infected peritoneal macrophages.

823 (A and B) BALB/c mice derived thioglycollate elicited peritoneal macrophages were either
824 uninfected or infected with *L. major* (Lm) promastigotes for 12hrs (A) or 30hrs (B) and Nramp1
825 protein level was examined by immunostaining using anti- Nramp1 antibody (Green).
826 *Leishmania* and macrophage nucleus was stained with DAPI (Blue). Arrows indicate the
827 presence of intracellular parasites in Lm infected macrophages. Cells were visualized with Zeiss
828 Apotome microscope using 63X oil immersion objective. Scale bar: 20 μ m. Lower panel shows
829 the relative fluorescence intensity of Nramp1 in uninfected (grey bar) and Lm infected (black
830 bar) macrophages at both the time points. Relative fluorescence intensity was measured from at
831 least 100 macrophage cells imaged under Olympus IX-81 epifluorescence microscope from three
832 independent experiments using ZEN software. Uninfected cells were used as reference sample.
833 Error bars represent SEM values calculated from the experiments. **, $p \leq 0.01$; ***, $p \leq 0.001$.

834 **FIG S3** Pharmacological inhibition of proteasome activity prevents *L. major* infection-induced
835 degradation of Nramp1.

836 (A) Uninfected, *L. major* (Lm) infected or 1 μ M MG132 treated Lm infected J774A.1
837 macrophage cells were lysed at 12hrs post infection and Nramp1 protein level was determined by
838 western blot. Blots were probed with anti-Nramp1 and anti- γ -Actin (as loading control)
839 antibodies. (B) Bar diagram showing relative intensity of Nramp1 protein in uninfected (grey),
840 Lm infected (black) and 1 μ M MG132 treated Lm infected (white) J774A.1 macrophages
841 measured from western blot data using ImageJ software as mentioned earlier. Error bars
842 represent SEM values calculated from at least three independent experiments. ***, $p \leq 0.001$;
843 ****, $p \leq 0.0001$.

844 **FIG S4** *L. major* infection stimulates hepcidin expression in macrophage both at mRNA at
845 protein level.

846 (A) J774A.1 macrophage cells were either uninfected or infected with *L. major* (Lm)
847 promastigotes for 12hrs and cDNA was been prepared from each of the samples. The hepcidin
848 mRNA level was then measured by RT-qPCR using β -Actin as endogenous control and
849 uninfected cells as reference sample. Error bars represent SEM values calculated from three
850 independent experiments. *, $p \leq 0.05$. (B) Uninfected or Lm infected J774A.1 macrophage cells at
851 12hrs post infection were fixed and immunostained using anti-hepcidin antibody (green).
852 Propidium iodide (PI, red) was used to stain parasite and host cell nucleus. Arrows indicate the
853 presence of intracellular parasites in Lm infected macrophages. Cells were visualized with Zeiss
854 Apotome microscope using 63X oil immersion objective. Scale bar: 20 μ m.

855 **FIG S5** Pharmacological inhibition of hepcidin transcription prevents Nramp1 degradation
856 without effecting cell viability.

857 (A) Uninfected, *L. major* (Lm) infected or 4µg/ml heparin treated Lm infected J774A.1
858 macrophage cells were lysed at 12hrs post infection and Nramp1 protein level was analyzed by
859 western blot using anti- Nramp1 and γ - Actin antibody (as loading control). (B) Bar diagram
860 shows relative intensity of Nramp1 protein in uninfected (grey), Lm infected (black) and 4µg/ml
861 heparin treated Lm infected (checker board pattern) J774A.1 macrophages measured from the
862 respective western blot data using ImageJ software. All the measurements were normalized using
863 uninfected cells as reference sample and γ - Actin as endogenous control. Error bars represent
864 SEM values calculated from three independent experiments. ***, $p \leq 0.001$; ****, $p \leq 0.0001$. (C)
865 J774A.1 macrophage cells were grown in presence of 4µg/ml heparin for 0-30hrs and cellular
866 viability was measured by trypan blue dye exclusion test. Cells were observed under 40X
867 magnification of inverted light microscope (Nikon). Error bars represent SEM values calculated
868 from three independent experiments.

Figure 1:




Figure 2:




Figure 3:








Figure 4:




Figure 5:




Figure 6:







Figure 7:





Supplementary 1:




Supplementary 2:



Supplementary 3:



Supplementary 4:



Supplementary 5:

